Allergan CEO Pyott steps down from Edwards' board; Philly jury sides with patient in Actos cancer case;

@FiercePharma: Top-read special report this weekend: Top 10 #pharma companies by employees - 2014. Report | Follow @FiercePharma

@CarlyHFierce: Here's a profile on Pfizer's Susan Silbermann, whose #Vaccines unit has recently scored some big wins. More | Follow @CarlyHFierce

> Allergan ($AGN) CEO David Pyott stepped down from the Edwards Lifesciences ($EW) board, saying he needed to devote more time to his job as chairman and CEO of Allergan; Pyott has been fighting a hostile bid from Valeant Pharmaceuticals ($VRX). Report

> A Philadelphia jury awarded $2 million in compensation to a woman who claimed Takeda Pharmaceutical's diabetes drug Actos caused her bladder cancer. Report

> Merck ($MRK) said it would offer three series of euro-denominated notes; it plans to use the proceeds to buy back older debt. Release

> European regulators encouraged patients to report suspected side effects of the medications they use. Release

> Mylan ($MYL) rolled out its version of the HIV combination treatment Combivir, sold by ViiV Healthcare, in the U.S. Release

> GlaxoSmithKline ($GSK) appointed Credit Suisse Chairman Urs Rohner to its board of directors. Release

Medical Device News

@FierceMedDev: $BD to buy CareFusion for $12.2B to become more hospital-focused. Story | Follow @FierceMedDev

@VarunSaxena2: Medtronic undeterred by new regs, to finance acquisition of Covidien with external funds. More | Follow @VarunSaxena2

@EmilyWFierce: Pain-management outfit Nevro heads to market with plans for $125M IPO. Article | Follow @EmilyWFierce

@MichaelGFierce: From our Women in Biotech Feature: Adelene Perkins of $INFI says, "Our endeavor is by definition a team sport." Report | Follow @MichaelGFierce

> Attorney questions FDA's authority to regulate devices promoted on social media. More

> BD to buy CareFusion for $12.2B to become more hospital-focused. Article

> Pain-management outfit Nevro heads to market with plans for $125M IPO. Story

Biotech News

@FierceBiotech: Check out our new feature: Top women in #biotech 2014. Special report | Follow @FierceBiotech

@JohnCFierce: Struggling $TEVA slashing R&D, chops 14 programs as it retreats on two fronts. More | Follow @JohnCFierce

@DamianFierce: $ZAFG's @TEHughes2009 on leaving Big Pharma for small biotech. Article | Follow @DamianFierce

@EmilyMFierce: Mining the microbiome for new therapeutics. Item | Follow @EmilyMFierce

> Novartis partners with Bristol-Myers Squibb as immuno-oncology deal frenzy heats up. More

> Actavis snaps up Durata, newly approved antibiotic in $675M buyout. Article

> Sunesis shares crushed in a rout after leukemia PhIII ends in defeat. News

CRO News

> WuXi snags a stateside CRO to beef up its early-stage services. News

> Catalent bets on armed antibodies with Redwood buyout. Report

> Chiltern picks up an Asian CRO with eyes on oncology. Story

> Accelovance poaches a Big Pharma vet to lead its oncology efforts. Article

> European CRO Genae stretches out in the U.S. Item

Biotech IT News

> EMA overturns ban on data downloads in final transparency policy. News

> Facebook mulls move into healthcare sector. Item

> Wall Street turns to social-listening tools to guide pharma bets. Report

> Google joins BRAIN Initiative to help with petabyte-scale data sets. Article

> IT projects grab slice of $102M round of PCORI funding. More

Animal Health News

> Report: Integrated Animal Health to roll out pain patches for pets, other animals. Story

> FAO says control of Madagascar locust plague threatened by lack of funds. Item

> Neogen acquires BioLumix through purchase of outstanding stock. News

> Ceva spends $23M to upgrade its sterile products plant in France. Article

> Kansas State researchers get $1.1M NIH grant to study swine flu. More

And Finally... A patent settlement doesn't have to include cash to qualify as a pay-for-delay deal under the U.S. Supreme Court's Actavis ($ACT) decision, a judge said. Report (reg. req.)

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.